These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 30824564)

  • 1. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease.
    Niu L; Geyer PE; Wewer Albrechtsen NJ; Gluud LL; Santos A; Doll S; Treit PV; Holst JJ; Knop FK; Vilsbøll T; Junker A; Sachs S; Stemmer K; Müller TD; Tschöp MH; Hofmann SM; Mann M
    Mol Syst Biol; 2019 Mar; 15(3):e8793. PubMed ID: 30824564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Hou W; Janech MG; Sobolesky PM; Bland AM; Samsuddin S; Alazawi W; Syn WK
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31860081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
    J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: a systematic review.
    Lădaru A; Bălănescu P; Stan M; Codreanu I; Anca IA
    Biomarkers; 2016; 21(2):102-14. PubMed ID: 26632636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of plasma tRNA fragments as a promising biomarker for liver fibrosis in nonalcoholic fatty liver disease.
    Huang P; Tu B; Liao HJ; Huang FZ; Li ZZ; Zhu KY; Dai F; Liu HZ; Zhang TY; Sun CZ
    Sci Rep; 2021 Mar; 11(1):5886. PubMed ID: 33723340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
    Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
    Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
    Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
    Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum proteome assessment in nonalcoholic fatty liver disease in children: a preliminary study.
    Małecki P; Tracz J; Łuczak M; Figlerowicz M; Mazur-Melewska K; Służewski W; Mania A
    Expert Rev Proteomics; 2020; 17(7-8):623-632. PubMed ID: 32921203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
    Harrison SA; Ratziu V; Boursier J; Francque S; Bedossa P; Majd Z; Cordonnier G; Sudrik FB; Darteil R; Liebe R; Magnanensi J; Hajji Y; Brozek J; Roudot A; Staels B; Hum DW; Megnien SJ; Hosmane S; Dam N; Chaumat P; Hanf R; Anstee QM; Sanyal AJ
    Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):970-985. PubMed ID: 32763196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.
    Younossi ZM; Karrar A; Pierobon M; Birerdinc A; Stepanova M; Abdelatif D; Younoszai Z; Jeffers T; Felix S; Jeiran K; Hodge A; Zhou W; Monge F; Alaparthi L; Chandhoke V; Goodman ZD; Petricoin EF
    BMC Med; 2018 Sep; 16(1):170. PubMed ID: 30205811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
    PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
    Williams KH; Vieira De Ribeiro AJ; Prakoso E; Veillard AS; Shackel NA; Brooks B; Bu Y; Cavanagh E; Raleigh J; McLennan SV; McCaughan GW; Keane FM; Zekry A; Gorrell MD; Twigg SM
    J Diabetes; 2015 Nov; 7(6):809-19. PubMed ID: 25350950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.
    Povero D; Eguchi A; Li H; Johnson CD; Papouchado BG; Wree A; Messer K; Feldstein AE
    PLoS One; 2014; 9(12):e113651. PubMed ID: 25470250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients.
    Yuan XX; Zhu HJ; Pan H; Chen S; Liu ZY; Li Y; Wang LJ; Lu L; Yang HB; Gong FY
    World J Gastroenterol; 2019 Apr; 25(14):1741-1752. PubMed ID: 31011258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.
    Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A
    Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease.
    Kumagai E; Mano Y; Yoshio S; Shoji H; Sugiyama M; Korenaga M; Ishida T; Arai T; Itokawa N; Atsukawa M; Hyogo H; Chayama K; Ohashi T; Ito K; Yoneda M; Kawaguchi T; Torimura T; Nozaki Y; Watanabe S; Mizokami M; Kanto T
    Sci Rep; 2016 Oct; 6():35282. PubMed ID: 27739482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
    Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
    World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress.
    Li BH; He FP; Yang X; Chen YW; Fan JG
    Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.